BR112017008840A2 - intensificador de inibidores do homólogo 2 de zeste - Google Patents
intensificador de inibidores do homólogo 2 de zesteInfo
- Publication number
- BR112017008840A2 BR112017008840A2 BR112017008840A BR112017008840A BR112017008840A2 BR 112017008840 A2 BR112017008840 A2 BR 112017008840A2 BR 112017008840 A BR112017008840 A BR 112017008840A BR 112017008840 A BR112017008840 A BR 112017008840A BR 112017008840 A2 BR112017008840 A2 BR 112017008840A2
- Authority
- BR
- Brazil
- Prior art keywords
- enhancer
- zeste homolog
- inhibitor enhancer
- inhibitor
- zeste
- Prior art date
Links
- 239000003623 enhancer Substances 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 title abstract 2
- 101150090105 Ezh2 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462069438P | 2014-10-28 | 2014-10-28 | |
| US201462075596P | 2014-11-05 | 2014-11-05 | |
| PCT/EP2015/075009 WO2016066697A1 (en) | 2014-10-28 | 2015-10-28 | Enhancer of zeste homolog 2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017008840A2 true BR112017008840A2 (pt) | 2017-12-19 |
Family
ID=54360465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017008840A BR112017008840A2 (pt) | 2014-10-28 | 2015-10-28 | intensificador de inibidores do homólogo 2 de zeste |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20170334891A1 (enExample) |
| EP (1) | EP3212639A1 (enExample) |
| JP (1) | JP6571180B2 (enExample) |
| KR (1) | KR20170068603A (enExample) |
| CN (1) | CN107148419A (enExample) |
| AU (1) | AU2015340614B2 (enExample) |
| BR (1) | BR112017008840A2 (enExample) |
| CA (1) | CA2965729A1 (enExample) |
| MA (1) | MA40848A (enExample) |
| RU (1) | RU2017118165A (enExample) |
| WO (1) | WO2016066697A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY36758A (es) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| WO2017191545A1 (en) | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| CA3050221C (en) | 2017-01-19 | 2021-09-28 | Daiichi Sankyo Company, Limited | Pharmaceutical composition used for treatment of htlv-1-associated myelopathy |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| WO2018177993A1 (de) | 2017-03-31 | 2018-10-04 | Bayer Cropscience Aktiengesellschaft | Pyrazole zur bekämpfung von arthropoden |
| FI4043466T3 (fi) | 2018-01-31 | 2024-10-30 | Mirati Therapeutics Inc | Prc2:n estäjiä |
| WO2019226491A1 (en) | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CA3104209A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| JP7624404B2 (ja) | 2019-04-22 | 2025-01-30 | ミラティ セラピューティクス，インク． | Ｐｒｃ２阻害剤としてのナフチリジン誘導体 |
| WO2020247475A1 (en) | 2019-06-05 | 2020-12-10 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer |
| KR20220041130A (ko) * | 2019-07-24 | 2022-03-31 | 콘스텔레이션 파마슈티칼스, 인크. | 암 치료를 위한 병용 요법에서의 ezh2 억제 |
| JP2022545467A (ja) | 2019-08-22 | 2022-10-27 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法 |
| CN110950834A (zh) * | 2019-11-26 | 2020-04-03 | 济南大学 | 新型eed-ezh2相互作用小分子抑制剂的确定和评价 |
| IL316421A (en) | 2022-04-27 | 2024-12-01 | Daiichi Sankyo Co Ltd | Combination of an antibody-drug conjugate with an EZH1 and/or EZH2 inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20170736T1 (hr) * | 2010-05-07 | 2017-07-28 | Glaxosmithkline Llc | Indoli |
| JO3438B1 (ar) * | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) * | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| EP2773754B1 (en) * | 2011-11-04 | 2016-08-03 | Glaxosmithkline Intellectual Property (No. 2) Limited | Compounds for use in the treatment of T-cell mediated diseases |
| EP2812001B1 (en) * | 2012-02-10 | 2017-06-14 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| UA111305C2 (uk) * | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| CA2910873A1 (en) * | 2013-04-30 | 2014-11-06 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| JP2016523955A (ja) * | 2013-07-10 | 2016-08-12 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ | Ｚｅｓｔｅホモログ２エンハンサー阻害剤 |
-
2015
- 2015-10-28 KR KR1020177014034A patent/KR20170068603A/ko not_active Withdrawn
- 2015-10-28 BR BR112017008840A patent/BR112017008840A2/pt not_active Application Discontinuation
- 2015-10-28 RU RU2017118165A patent/RU2017118165A/ru not_active Application Discontinuation
- 2015-10-28 MA MA040848A patent/MA40848A/fr unknown
- 2015-10-28 WO PCT/EP2015/075009 patent/WO2016066697A1/en not_active Ceased
- 2015-10-28 CA CA2965729A patent/CA2965729A1/en not_active Abandoned
- 2015-10-28 AU AU2015340614A patent/AU2015340614B2/en not_active Ceased
- 2015-10-28 CN CN201580058856.7A patent/CN107148419A/zh active Pending
- 2015-10-28 EP EP15786958.7A patent/EP3212639A1/en not_active Withdrawn
- 2015-10-28 US US15/522,373 patent/US20170334891A1/en not_active Abandoned
- 2015-10-28 JP JP2017522890A patent/JP6571180B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017532360A (ja) | 2017-11-02 |
| RU2017118165A3 (enExample) | 2018-12-10 |
| WO2016066697A1 (en) | 2016-05-06 |
| CN107148419A (zh) | 2017-09-08 |
| AU2015340614B2 (en) | 2018-07-19 |
| US20170334891A1 (en) | 2017-11-23 |
| AU2015340614A1 (en) | 2017-05-18 |
| MA40848A (fr) | 2021-05-05 |
| CA2965729A1 (en) | 2016-05-06 |
| JP6571180B2 (ja) | 2019-09-04 |
| EP3212639A1 (en) | 2017-09-06 |
| KR20170068603A (ko) | 2017-06-19 |
| RU2017118165A (ru) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017008840A2 (pt) | intensificador de inibidores do homólogo 2 de zeste | |
| BR112015027527A2 (pt) | intensificador de inibidores do homólogo zeste 2 | |
| BR112018072740A2 (pt) | realçador de inibidores de homólogo 2 de zeste | |
| PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| BR112015030515A2 (pt) | intensificadores de inibidores de homólogo 2 de zeste | |
| BR112017028616A2 (pt) | acentuador de inibidores de homólogo de zeste 2 | |
| BR112016018555A8 (pt) | Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1 | |
| DOP2017000109A (es) | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos | |
| BR112017022604A2 (pt) | composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação | |
| BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
| BR112016015838A8 (pt) | compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação | |
| MX373373B (es) | Inhibidores de desmetilasa-1 específica de lisina. | |
| MX2016011810A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| EA201790082A1 (ru) | Ингибиторы лизин-специфической демитилазы-1 | |
| EA201890331A1 (ru) | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена | |
| BR112017006002A2 (pt) | compostos de imidazopiridazina e seu uso | |
| TR201900148T4 (tr) | Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. | |
| BR112016028037A2 (pt) | Novos compostos | |
| CR20170513A (es) | Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap). | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| BR112017003881A2 (pt) | derivados do n-aril-2-amino-4-aril-pirimidinas poliéteres macrocíclicos como inibidores da ftl3 e jak | |
| BR112018009646A2 (pt) | compostos de glicolipídeo e seus usos no tratamento de tumores | |
| MX2017007926A (es) | Derivados de fumagilol. | |
| BR112019000603A2 (pt) | composto, composição farmacêutica, método para o tratamento de doenças e uso do composto | |
| BR112018010616A2 (pt) | compostos inibidores seletivos de mmp-12 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |